<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04501068</url>
  </required_header>
  <id_info>
    <org_study_id>MULTIAURAGAIN</org_study_id>
    <nct_id>NCT04501068</nct_id>
  </id_info>
  <brief_title>Evaluation of the Ambu® AuraGain in Ambulatory Surgery</brief_title>
  <official_title>Analysis of 150 Consecutive Uses of the Ambu® AuraGain Supraglottic Airway by One Anaesthetist in Ambulatory Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Universitario Gregorio Marañon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General Universitario Gregorio Marañon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was designed to evaluate the success rate, time of insertion, sealing efficacy and&#xD;
      security of the Ambu® AuraGain in patients undergoing ambulatory surgery by one anesthetist&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Supraglottic devices (SGD), in all their different forms, have become an authentic innovation&#xD;
      in airway management especially in day surgery. The Ambu® AuraGainTM (Ambu A/S, Ballerup,&#xD;
      Denmark) is a new single-use, anatomically curved supraglottic airway with an integrated&#xD;
      gastric access port designed to provide functional separation of the respiratory and&#xD;
      digestive tracts allowing the exit of gastric contents and the passage of a gastric tube to&#xD;
      manage gastric contents.&#xD;
&#xD;
      Its characteristics in the design, composition by a smooth and atraumatic material, the&#xD;
      presence of the gastric drainage access, with potential improved patient safety and its&#xD;
      characteristic of being disposable, suggests a significant expansion of its use in the coming&#xD;
      years.&#xD;
&#xD;
      The series in the literature reporting performance or safety of use of the Ambu® AuraGainTM&#xD;
      come from studies on selected cases and in certain surgical procedures. However, there are&#xD;
      limited studies that have evaluated the efficacy of the device in routine clinical practice&#xD;
      in patients intervened in ambulatory surgery and performed by a single investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the number of attempts to insert the Ambu® AuraGainTM supraglottic airway</measure>
    <time_frame>The number of insertion attempts will be collected after anesthesia induction</time_frame>
    <description>Insertion attempts (in numbers)&#xD;
From picking up the Ambu® AuraGainTM supraglottic airway until the mask is placed into the patient mouth. (in numbers)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the time to insert the Ambu® AuraGainTM supraglottic airway</measure>
    <time_frame>The insertion time will be collected after anesthesia induction after administration of propofol</time_frame>
    <description>The time from picking up the Ambu® AuraGainTM supraglottic airway until the cuff was inflated. (in seconds)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure during insertion of the Ambu® AuraGainTM supraglottic airway</measure>
    <time_frame>At baseline and every 3 minutes until 6 minutes after insertion of the Ambu® AuraGainTM supraglottic airway</time_frame>
    <description>Blood pressure in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate during insertion of the Ambu® AuraGainTM supraglottic airway heart rate</measure>
    <time_frame>At baseline and every 3 minutes until 6 minutes after insertion of the Ambu® AuraGainTM supraglottic airway]</time_frame>
    <description>Heart rate in beep per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIS data</measure>
    <time_frame>At baseline and every 3 minutes until 6 minutes after insertion of the Ambu® AuraGainTM supraglottic airway (To evaluate the evolution of BIS values during insertion of the Ambu® AuraGainTM supraglottic airway</time_frame>
    <description>Bis data: number from 100 (awake) to 40-45 (anesthetic status)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oropharyngeal leak pressure of the Ambu® AuraGainTM supraglottic airway.</measure>
    <time_frame>The Oropharyngeal leak pressure of the Ambu® AuraGainTM supraglottic airway will be collected 10 minutes after the Ambu® AuraGainTM supraglottic airway will be inserted]</time_frame>
    <description>The Oropharyngeal leak pressure of the Ambu® AuraGainTM supraglottic airway will be determined with an intracuff pressure of 60 cm H2O by closing the expiratory valve of the breathing circle circuit at a fixed gas flow of 3 L/min and noting the pressure at which an oropharyngeal leak occurs. (in cm H2O)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">150</enrollment>
  <condition>Airway</condition>
  <arm_group>
    <arm_group_label>Ambu AuraGain</arm_group_label>
    <description>Ambu® AuraGainTM Patients undergoing anesthesia in which airway management includes a Ambu® AuraGainTM supraglottic airway and fulfill the inclusion criteria of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ambu® AuraGainTM</intervention_name>
    <description>Evaluate the time of insertion, performance, security and insertion success rate of the Ambu® AuraGainTM in patients undergoing ambulatory surgery and general anaesthesia</description>
    <arm_group_label>Ambu AuraGain</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients scheduled for outpatient surgery. Patients who require the insertion of a&#xD;
        supraglottic device as part of their anesthetic management.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing surgery procedures in ambulatory surgery usually performed with&#xD;
             supraglottic devices.&#xD;
&#xD;
          -  ASA physical status I-III patients&#xD;
&#xD;
          -  Age 18-no limit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known difficult airway&#xD;
&#xD;
          -  Patients with increased risk of aspiration&#xD;
&#xD;
          -  Patient refusal to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Hortal, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Servicio de Anestesiología, Hospital General Universitario Gregorio Marañón</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Shariffuddin II, Teoh WH, Tang E, Hashim N, Loh PS. Ambu® AuraGain™ versus LMA Supreme™ Second Seal™: a randomised controlled trial comparing oropharyngeal leak pressures and gastric drain functionality in spontaneously breathing patients. Anaesth Intensive Care. 2017 Mar;45(2):244-250.</citation>
    <PMID>28267947</PMID>
  </results_reference>
  <results_reference>
    <citation>Wong DT, Ooi A, Singh KP, Dallaire A, Meliana V, Lau J, Chung F, Singh M, Wong J. Comparison of oropharyngeal leak pressure between the Ambu® AuraGain™ and the LMA® Supreme™ supraglottic airways: a randomized-controlled trial. Can J Anaesth. 2018 Jul;65(7):797-805. doi: 10.1007/s12630-018-1120-4. Epub 2018 Mar 26.</citation>
    <PMID>29582360</PMID>
  </results_reference>
  <results_reference>
    <citation>Lopez AM, Agusti M, Gambus P, Pons M, Anglada T, Valero R. A randomized comparison of the Ambu AuraGain versus the LMA supreme in patients undergoing gynaecologic laparoscopic surgery. J Clin Monit Comput. 2017 Dec;31(6):1255-1262. doi: 10.1007/s10877-016-9963-0. Epub 2016 Nov 26.</citation>
    <PMID>27889843</PMID>
  </results_reference>
  <results_reference>
    <citation>Preece G, Ng I, Lee K, Mezzavia P, Krieser R, Williams DL, Stewart O, Segal R. A randomised controlled trial comparing fibreoptic-guided tracheal intubation through two supraglottic devices: Ambu® AuraGain™ laryngeal mask and LMA® Fastrach™. Anaesth Intensive Care. 2018 Sep;46(5):474-479.</citation>
    <PMID>30189821</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 28, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General Universitario Gregorio Marañon</investigator_affiliation>
    <investigator_full_name>Matilde Zaballos</investigator_full_name>
    <investigator_title>Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>Ambu® AuraGainTM</keyword>
  <keyword>Second Generation Laryngeal Masks Airway</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

